OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms
OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various…
1,670$
1,83%
Echtzeit-Aktienkurs OKYO Pharma Ltd. (ADRs)
Bid:
Ask:
Nachrichten zur OKYO Pharma Ltd. (ADRs) Aktie
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the…
OKYO Pharma to release Phase 2 dry eye disease trial results on Friday
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…
OKYO Pharma to release Phase 2 dry eye disease trial results
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…